Risk factors and clinical outcomes of extended spectrum beta-lactamase (esbl)-producing escherichia coli septicemia at Arinagarind University Hospital, Thailand

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 43, Issue 5, 2012, Pages 1169-1177

  Anunnatsiri, Sirluck ^a   Towiwat, Patapong ^a   Chaimanee, Prajuab ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Esbl; Escherichia coli; Septicemia; Thailand

Indexed keywords

EID: 84868100572     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Chayakulkeeree M, Junsriwong P, Keerasuntonpong A, Tribuddharat C, Thamlikitkul V. Epidemiology of extended-spectrum beta-lactamases producing gram-negative bacilli at Siriraj Hospital, Thailand, 2003. Southeast Asian J Trop Med Public Health 2005; 36: 1503-9.
2. Gudiol C, Calatayud L, Garcia-Vidal C, et al. Bacteraemia due to extended-spectrum beta-lactam-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65: 333-41.
3. Hawser SP, Bouchillon SK, Hoban DJ, et al. Emergence of high levels of extended-spectrum-beta-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009; 53: 3280-4.
4. Ingviya N, Hortiwakul R, Chayakul P, Thamjarungwong B. Prevalence and susceptibility patterns of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta lactamases in Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2003; 20: 127-34.
5. Kang CL, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumonia: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48: 4574-81.
6. Melzer M, Peterson I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007; 55: 254-9.
7. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved Standard M7-A5. Wayne, PA: NCCLS, 2000.
8. Rodriguez-Bano J, Navarro MD, Romero L, et al. Risk factors for emerging bloodstream infections caused by extended-spectrum b-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14: 180-3.
9. Rodriguez-Bano J, Picon E, Gijon P, et al. Risk factors and prognosis of nosocomial bloodstream infections caused by extended-spectrum-b-lactamase-producing Escherichia coli. J Clin Microbiol 2010; 48: 1726-31.
10. Tharavichitkul P, Khantawa B, Bousoung V, Boonchoo M. Activity of fosfomycin against extended-spectrum b-lactamases-producing Klebsiella pneumoniae and Escherichia coli in Maharaj Nakorn Chiang Mai Hospital. J Infect Dis Antimicrob Agents 2005; 22: 121-6.
11. Thom KA, Schweizer ML, Orih RB, et al. Impact of empirical antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: a cohort study. BMC Infect Dis 2008; 8: 116.
12. Tumbarello M, Sali M, Trecarichi EM, et al. Bloodstream infections caused by extended-spectrum-b-lactamase-producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008; 52: 3244-52.
13. Waiwarawooth J, Jutiworakul K, Joraka W. The prevalence and susceptibility patterns of ESBL-producing Klebsiella pneumoniae and Escherichia coli in Chonburi Hospital. J Infect Dis Antimicrob Agents 2006; 23: 57-65.
14. Wu UI, Yang CS, Chen WC, Chen SC, Chen YC. Risk factors for bloodstream infections due to extended-spectrum b-lactamase-producing Escherichia coli. J Microbiol Immunol Infect 2010; 43: 310-6.